Physician profile
Eric Matthew Edgar
NPI 1972744894
$6,749.57
in general payments reported to CMS, 2019-2025
42 companies · $678 in 2025
The $678 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $344 · 2021: $1,064 · 2022: $1,086 · 2023: $1,317 · 2024: $1,692 · 2025: $678.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,687.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $916.78 | 2019-2025 | Botox, Ubrelvy, Qulipta |
| Emd Serono, INC. | $756.66 | 2019-2025 | Mavenclad |
| Ucb, INC. | $417.61 | 2019-2024 | Fintepla, Briviact |
| Novartis Pharmaceuticals Corporation | $378.50 | 2019-2025 | |
| Sk Life Science, INC. | $341.26 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $337.47 | 2019-2024 | Austedo, Austedo Xr |
| Alexion Pharmaceuticals, INC. | $240.77 | 2019-2024 | Ultomiris, Soliris |
| Boston Scientific Corporation | $234.15 | 2024-2025 | Vercise, General - Dbs |
| Argenx US, INC. | $232.20 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Neurocrine Biosciences, INC. | $230.72 | 2020-2024 | Ingrezza, Ongentys |
| Lilly USA, LLC | $218.02 | 2019-2024 | Emgality, Reyvow, Amyvid |
| Biogen, INC. | $217.08 | 2019-2024 | Tysabri, Vumerity, Skyclarys |
| Celgene Corporation | $159.60 | 2022-2024 | Zeposia |
| Allergan, INC. | $149.46 | 2019-2022 | |
| Kyowa Kirin, INC. | $148.05 | 2020-2024 | Nourianz |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $111.84 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Sunovion Pharmaceuticals INC. | $111.33 | 2021-2022 | |
| Lundbeck LLC | $107.16 | 2019-2024 | Vyepti |
| Acorda Therapeutics, INC | $107.06 | 2019-2023 | Inbrija |
| Acadia Pharmaceuticals INC | $104.02 | 2019-2024 | Nuplazid |
| Genzyme Corporation | $103.07 | 2019-2023 | |
| Harmony Biosciences LLC | $101.79 | 2020-2023 | Wakix |
| Tanabe Pharma America, INC. | $94.46 | 2021-2023 | |
| Jazz Pharmaceuticals INC. | $92.33 | 2020-2024 | Epidiolex |
| Pfizer INC. | $79.98 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $74.26 | 2023-2024 | Nuedexta, Rexulti |
| Biohaven Pharmaceuticals, INC. | $72.74 | 2021 | |
| Abbott Laboratories | $71.46 | 2023-2024 | Infinity |
| Tg Therapeutics, INC. | $65.90 | 2025 | |
| Amgen INC. | $57.44 | 2022-2023 | Aimovig |
| Livanova USA, INC. | $52.42 | 2019-2022 | |
| Horizon Therapeutics Plc | $51.31 | 2021-2022 | |
| Avadel Cns Pharmaceuticals, LLC | $50.18 | 2023-2024 | Lumryz |
| Biohaven Pharmaceutical Holding Company LTD. | $49.84 | 2022 | |
| Grifols USA, LLC | $40.52 | 2021-2024 | Gamunex-C |
| Csl Behring | $35.83 | 2022-2024 | Hizentra |
| Mdd US Operations, LLC | $30.56 | 2019 | |
| Amneal Pharmaceuticals LLC | $26.19 | 2022-2023 | Rytary |
| Catalyst Pharmaceuticals, INC. | $24.24 | 2019 | |
| Merz Pharmaceuticals, LLC | $24.09 | 2024 | Xeomin |
| Octapharma USA, INC. | $20.02 | 2023 | Panzyga |
| Sumitomo Pharma America, INC. | $11.20 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Edgar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.